Literature DB >> 2949069

Ribavirin inhibits mast cell mediator release.

D L Marquardt, H E Gruber, L L Walker.   

Abstract

Ribavirin (1-beta-D-ribofuranosyl-1,2-4-triazole-3-carboxamide) is a promising antiviral agent as well as a structural analog of guanosine. Although at different concentrations it has been reported to induce either immunosuppression or immune stimulation, its effects upon immediate hypersensitivity reactions are largely unknown. Because purine metabolism appears to be important in mast cell secretion, the effects of ribavirin on mouse bone marrow-derived mast cell functions were investigated. When ribavirin was added to mast cells at the time of stimulation with A23187 or specific antigen, no effect on the release of beta-hexosaminidase, a preformed mediator, was evident. However, mast cells cultured in 1 to 20 microM ribavirin for 1 to 7 days exhibited dose- and time-dependent inhibitions of stimulated beta-hexosaminidase and leukotriene C4 releases without altering mast cell mediator content. This inhibition occurred even when ribavirin had no effect on cell growth. A concomitant decrease in antigen-challenged mast cell intracellular Ca concentration was also observed after ribavirin treatment. Chronic ribavirin exposure in vitro inhibits mast cell secretory processes stimulated by both immunoglobulin E- and nonimmunoglobulin E-related signals. Its precise mechanism of action and any potential efficacy as an antiallergic agent remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2949069

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Regulation of exocytosis from rat peritoneal mast cells by G protein beta gamma-subunits.

Authors:  J A Pinxteren; A J O'Sullivan; P E Tatham; B D Gomperts
Journal:  EMBO J       Date:  1998-11-02       Impact factor: 11.598

2.  In vitro and in vivo effects of ribavirin on human respiratory epithelium.

Authors:  L Y Han; R Wilson; S Slater; A Rutman; R C Read; N J Snell; P J Cole
Journal:  Thorax       Date:  1990-02       Impact factor: 9.139

Review 3.  Economic and long-term benefits of ribavirin therapy on respiratory syncytial virus infection.

Authors:  N J Snell
Journal:  Lung       Date:  1990       Impact factor: 2.584

4.  Interferon-alpha/beta inhibits IgE-dependent histamine release from rat mast cells.

Authors:  M Swieter; W A Ghali; C Rimmer; D Befus
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

5.  Purification and identification of FOAD-II, a cytosolic protein that regulates secretion in streptolysin-O permeabilized mast cells, as a rac/rhoGDI complex.

Authors:  A J O'Sullivan; A M Brown; H N Freeman; B D Gomperts
Journal:  Mol Biol Cell       Date:  1996-03       Impact factor: 4.138

6.  Ribavirin and alpha interferon enhance death receptor-mediated apoptosis and caspase activation in human hepatoma cells.

Authors:  Stephan F Schlosser; Markus Schuler; Christoph P Berg; Kirsten Lauber; Klaus Schulze-Osthoff; Friedrich Wilhelm Schmahl; Sebastian Wesselborg
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

7.  Guanine nucleotide is essential and Ca2+ is a modulator in the exocytotic reaction of permeabilized rat mast cells.

Authors:  T H Lillie; B D Gomperts
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

8.  Two G-proteins act in series to control stimulus-secretion coupling in mast cells: use of neomycin to distinguish between G-proteins controlling polyphosphoinositide phosphodiesterase and exocytosis.

Authors:  S Cockcroft; T W Howell; B D Gomperts
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

9.  Effects of ribavirin on cytokine production of recall antigens and phytohemaglutinin-stimulated peripheral blood mononuclear cells. (Inhibitory effects of ribavirin on cytokine production).

Authors:  Silvia Sookoian; Gustavo Castaño; Diego Flichman; Jerónimo Cello
Journal:  Ann Hepatol       Date:  2004 Jul-Sep       Impact factor: 2.400

Review 10.  Pharmacological treatment options for mast cell activation disease.

Authors:  Gerhard J Molderings; Britta Haenisch; Stefan Brettner; Jürgen Homann; Markus Menzen; Franz Ludwig Dumoulin; Jens Panse; Joseph Butterfield; Lawrence B Afrin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-04-30       Impact factor: 3.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.